Despite these observations, we do not consider that the putative tumor suppressor activity of RasGRF2 is a plausible explanation for the results reported here, because the Rasgrf2 deficiency only contributes to tumorigenesis when combined with the Vav1 proto–oncogene loss. The gene discussed is RASGRF2; the disease is neoplasm.